<DOC>
	<DOCNO>NCT01182077</DOCNO>
	<brief_summary>The objective study characterize effect multiple dos ASP015K pharmacokinetics single dose midazolam .</brief_summary>
	<brief_title>A Study Assess Drug Interaction ASP015K Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subject weigh least 45kg BMI 1832 kg/m2 , inclusive If female , subject least 2 year post menopausal surgically sterile per documentation provide third party medical professional subject pregnant document negative serum pregnancy test If male , subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy study period History clinically significant disorder , disease malignancy exclude nonmelanoma skin cancer Recent history ( within 6 month ) drug alcohol abuse positive urine screen drug abuse/illegal drug Treatment prescription drug complementary alternative medicine ( CAM ) within 14 day prior study drug administration , counter medication within 1 week prior study drug administration A symptomatic , viral , bacterial fungal infection within 1 week prior clinic checkin Positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) History human immunodeficiency virus ( HIV ) antibody Positive tuberculosis ( TB ) skin test Quantiferon Gold test Vaccinated within last 30 day prior study drug administration Received experimental agent within 30 day five halflives , whichever longer , prior study drug administration Any significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Absolute neutrophil count ( ANC ) &lt; 2500 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>midazolam</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>